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 Innovation in the medical device industry is crucial to continuously improve the health 
and wellbeing of society. The U.S. Food and Drug Administration (FDA) is responsible for 
ensuring the safety and effectiveness of medical devices on the market while balancing the need 
for continuous innovation. One way the FDA has tried to support innovation is through the 
development of the 510(k) pathway, which does not require clinical testing as the safety of the 
device is determined based on a predicate device. Many companies choose to develop products 
that can obtain approval through the 510(k) pathway. While the 510(k) pathway is shorter, it 
does not allow for the type of rapid innovation and approval needed during a public health 
emergency. The FDA has an alternate path, the Emergency Use Authorization (EUA), that 
authorizes the use of certain devices during pandemics such as COVID-19.  
 The goal of this thesis was to identify the ways in which the COVID-19 EUA encouraged 
innovation in the ventilator industry. The EUA provides an opportunity for new devices, 
technologies, and players to enter the industry that would otherwise face regulatory barriers. This 
study was completed using publicly available data to identify historical patterns in the ventilator 
industry, changes in the industry from the 510(k) to the EUA, and innovation in ventilator 
development. The analysis showed that there were new entrants to the ventilator market and 
companies took multiple approaches to innovative solutions, from manufacturing to product 
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Innovation is vital not only for the economy but for society as well. Problems and needs 
of society are constantly changing, and the continuous nature of innovation allows needs to 
remain fulfilled. This need for constant innovation is prominent in the medical device industry, 
yet the medical device industry is one where innovation has been slow (Bergsland, Elle, & Fosse, 
2014). The Food and Drug Administration (FDA) has tried to combat barriers to innovation by 
establishing multiple device approval pathways. 
The FDA implemented the Medical Device Amendments Act of 1976 to ensure the safety 
and effectiveness of medical devices. This act defined the premarket approval (PMA) and 
premarket notification (PMN) 510(k) pathways that are still in use today. The PMA is utilized 
for high-risk devices and is expected to have a 180-day review process. The 510(k) is a quicker 
process, with a projected timeline of 90 days, and is used for low to medium risk devices. The 
510(k)-process had two public health goals: to ensure that medical devices are safe and effective 
while facilitating innovation. Soon after the 510(k) was established, it became clear that it was 
not meeting its goal of facilitating innovation while maintain product safety. The medical device 
industry had raised concerns about the 510(k) process being unpredictable and not transparent, 
which suppressed innovation and led to more devices being sent overseas rather than in the 
United States (US) (FDA 510(k) Report, 2010). In addition to inhibiting innovation, safety 
requirements were still not being met, and studies found that devices approved through the 
510(k) from 2005 to 2009 were involved in 71% of device recalls that resulted in severe health 
impacts or death (Zuckerman, Brown, & Nissen, 2011). There is a delicate balance between 




The 510(k) is one of the shorter FDA processes, but the timeline of 90 days and the 
administrative burden of submission does not allow it to be useful in times of a public health 
crisis, such as coronavirus. The Emergency Use Authorization (EUA) of Medical Products was 
established in 2008. The EUA is meant to promote the development and availability of specific 
medical devices and products during national emergencies (FDA EUA, 2017). Medical devices 
that obtain EUA authorizations are only valid for when the public health emergency is a concern. 
The timeline for authorization is not explicitly stated, but it is significantly shorter than the 
510(k) approval process. Both the 510(k) and EUA pathways have goals of promoting medical 
device innovation.  
COVID-19 is a respiratory virus that was deemed a public health emergency in January 
2020. Patients with severe symptoms often require the support of a ventilator. An EUA was 
enacted during COVID-19 for certain medical devices, including ventilators. Hospitals typically 
have a limited supply of full-service ventilators that are expensive and complex to use. In the 
event of a respiratory virus pandemic, ventilator shortages are a significant concern (Kulish, 
Kliff, & Silver-Greenberg, 2020). In the case of COVID-19, the EUA allowed for alternative 
uses of existing medical devices and temporary authorization of new ventilator designs. 
This thesis will examine how a shift in regulatory procedure and expectations can impact 
innovative solutions in the medical device industry, specifically related to ventilators considering 
the COVID-19 pandemic. The first part of my thesis will be a literature review on barriers to 
innovation in the medical device industry and early innovative responses to COVID-19. I then 
discuss my research question and outline the methodology for data collection and analysis. I then 
present the findings from my research and discuss the nature of innovation in EUA authorized 






In late December 2019, Wuhan China reported a cluster of pneumonia cases. These cases 
were identified to be severe acute respiratory syndrome (SARS) - 2019 novel coronavirus. By 
January 30, the World Health Organization (WHO) declared a public health emergency of 
international concern (WHO, 2020). Since then, the exponential global spread of COVID-19 has 
led governments across the world to take various precautions to attempt to slow the spread and 
treat this disease.  
COVID-19 is a severe respiratory disease that has severe short and long-term impacts on 
the breathing capabilities of persons who contract the disease. Patients who experience severe 
symptoms often need a ventilator’s assistance to ensure proper exchange of oxygen and carbon 
dioxide into and out of the body. Ventilators have been in high demand since the beginning of 
the pandemic, and many countries have been aware of the shortage of ventilators (Kliff, 
Satariano, Silver-Greenberg, & Kulish, 2020). One study has estimated the projected need for 
invasive and noninvasive ventilators by studying recent COVID-19 hospitalizations (Wells, et 
al., 2020). Table 1 shows there is a 45,341 invasive ventilator shortage and a 77,289 noninvasive 
ventilator shortage in the United States (U.S.) as of October 2020. 
Table 1: Projected Need for Ventilators in the USA at COVID-19 Peak (Wells, et al., 2020) 
 Invasive Ventilator Count 
Noninvasive Ventilator 
Count 
Total Estimated Need 115,001 89,788 
Current Inventory 98,015 22,976 
Non COVID-19 Use 28,355 10,477 
Available for COVID-19 
Use 
69,660 12,499 





Current intensive care ventilators can cost as much as $50,000 and are complex machines 
with thousands of components that require highly trained professionals to operate them. As of 
March 18, 2020, American and international ventilator manufacturers said they would not be 
able to meet the soaring demand for ventilators anytime soon (Kliff, Satariano, Silver-Greenberg, 
& Kulish, 2020). Additionally, less than a dozen U.S. companies make ventilators. Foreign 
companies make about half the intensive care ventilators used in the U.S., and COVID-19 has 
caused a massive delay in shipping these ventilators to customers in the United States and 
elsewhere (Kliff, Satariano, Silver-Greenberg, & Kulish, 2020). One measure that the FDA has 
taken to combat the shortage of ventilators is the Emergency Use Authorization (EUA) for 
COVID-19 medical devices, which will be explained more in the following section. 
FDA Pathways  
 There are multiple pathways to approval for a medical device based on its classification. 
The device classification defines the risk associated with the device and determines the level of 
inspection and materials needed for the FDA review (FDA Pathway to Approval, 2018). 
Class I: Low-risk devices – only require general control. Most are exempt from 
premarket submissions.  
Class II: Moderate risk – require general and specific controls. The typical pathway is the 
Premarket Notification (PMN) 510(k). 
Class III: Life-supporting or life-sustaining devices – Typically require Premarket 
Approval (PMA). 
 Ventilators are considered a class II device, so they must go through the 510(k) process. 
Under the 510(k) pathway, companies identify substantial equivalence to a predicate device. 




technological characteristics as a prior approved device. Companies do not need to complete 
clinical trials for the 510(k), as substantial equivalence is meant to prove that the new device will 
be at least as safe and effective as the predicate device (FDA Pathway to Approval, 2018). The 
510(k) pathway is preferred by companies as there are fewer filing requirements, and the process 
is generally quicker and less expensive than the PMA pathway. 
 The EUA pathway is enacted by the FDA when a public health emergency can 
significantly affect the health and security of the United States. As stated by the FDA (FDA 
EUA COVID-19, 2020),  
“Section 564 of the Federal Food, Drug, and Cosmetic Act the FDA may allow 
unapproved medical products or unapproved uses of approved medical products to be 
used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or 
conditions when there are no adequate, approved, and available alternatives”  
Devices approved through the EUA can only be used while the EUA is in order. Once the 
public health emergency is resolved, the products must be taken off the market or returned to 
their original intended use. COVID-19 EUA’s have been enacted in the following categories: 
blood purification devices, hemodialysis devices, In Vitro diagnostics, decontamination systems 
for personal protective equipment (PPE), infusion pumps, PPE, remote or wearable patient 
monitoring devices, respiratory assist devices, ventilators, ventilator accessories, and other 
medical devices. The EUA contains fewer barriers than other FDA pathways, as its main goal is 







 This literature review aimed to identify and understand barriers to innovation in the 
medical device industry and see what was already known about innovative responses during 
COVID-19. The first part of the review analyzes the most common barriers to innovation and 
how these barriers affect the amount and type of innovation in the medical device industry. The 
second part of the literature review analyzes innovative responses to COVID-19 to identify what 
is already known and what needs to be studied further. 
Barriers to Medical Device Innovation 
 Innovation in the medical device industry is crucial to both improving existing solutions 
and creating novel solutions. As shown in Table 2, the most common impacts on medical device 
innovation mentioned in the literature were regulatory processes, firm size, academia and 
industry, and pricing.  
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 The most common barrier to innovation mentioned in the medical device industry is the 
regulatory process. The FDA has regulatory pathways in place to help ensure the safety and 
effectiveness of devices that enter the market. An intensive process is beneficial for determining 
the safety of devices, but there are aspects of the process that have negatively impacted 
innovation in the medical device industry.  
 The biggest issue of the FDA regulatory process is its unpredictability, which can affect 
the length and cost of the approval process. An unpredictable process leaves firms hesitant to 
introduce new products as they do not know how long it will take to get a return on their 
investment (Krucoff, Brindis, Hodgson, Mack, & Holmes, 2012). A slow and costly process also 
makes it difficult for small or new firms to enter the industry. Small firms do not have financial 
stability, and the lag time between creating a device and getting it onto the market can be 
detrimental for the business (Roberts, 1988). With an unpredictable process, firms of all sizes are 
hesitant to create new products for approval. 
 Additionally, as seen in the table above, the medical device industry has conservative 
medical patterns. Approval time for new and innovative devices is significantly longer than if 
substantial equivalence to a predicate can be claimed, allowing the use of the 510(k) pathway. 
Bergsland et al. (2014) perceive the 510(k) pathway as a disincentive to be the first firm to create 
a new product. Companies choose to pursue “me too” products more often as the process is less 
burdensome. A novel claim is not worth the regulatory risk for many firms (Bayon, et al., 2016). 
This conservative medical pattern is not only seen in the regulatory pathway but in places of care 




technologies to become the standard of care (Bergsland, Elle, & Fosse, 2014). Conservative 
patterns will be discussed further in the pricing section below. 
Barriers to Innovation based on Firm Size 
 As mentioned in the regulatory processes section, some barriers pose a greater risk to 
firms based on their size. Smaller companies are more likely to pursue early-stage innovation 
and produce novel products. Small firms are typically started to fill a need in the market that has 
not been met yet (Roberts, 1988). One example of this is solutions for orphan diseases. Orphan 
diseases are rare diseases that affect less than 200,000 people in the U.S., and most devices made 
for this group are created by small firms, as large firms generally want to focus on a larger 
market (Kahn, 1991). Early innovation is typically done on a smaller scale, and small firms often 
create disruptive technology that becomes a target for large firms. Bayon et al. (2016) mention 
that there has been a decline in the rate of innovation at the industry level. When larger 
companies do innovate, they typically focus on the end of the development process, such as 
improving existing devices rather than producing new ones.  
 Another source of innovation for medical devices are devices created at universities. 
Bergsland et al. (2014) mention that new devices often stem from academia, which has created 
conflicts in partnerships between universities and firms. Academic projects are typically 
completed with the goal of publication, but this can interfere with intellectual property rights for 
a firm. High approval costs and complicated processes also make it difficult for universities to 
pursue approval for novel devices on their own (Goodman & Gelijns, 1996). Since small firms 
and universities are often the ones creating novel devices, a costly and unpredictable regulatory 





 An additional barrier mentioned by four of the studies are concerns around product 
reimbursement and insurance. Market sizes for medical devices are relatively small compared to 
other markets such as personal electronics. Smaller market sizes lead to higher-priced products, 
this way, a company can still to produce a profit (Bergsland, Elle, & Fosse, 2014). Many medical 
devices are too costly for an average person to pay for on their own. This is where pricing 
impacts innovation. 
 First, insurance coverage can be unpredictable. Insurance often will not cover a device 
until its effectiveness has been proven. This is difficult for firms as hospitals are hesitant to 
introduce new technology unless significant cost-effectiveness is shown or the device has a huge 
value for society (Kahn, 1991). Companies tend to design devices that are reimbursable within 
existing insurance codes, but this can put a cap on the amount of innovation involved.  
 Second, there is no promise that insurance will cover a device, which discourages the 
introduction of new technology by companies. Minimal to no insurance coverage would decrease 
profitability for the firm as healthcare providers would hesitate to recommend a device that 
patients need to pay for out of pocket (Bayon, et al., 2016). Additionally, reimbursement 
decisions are ambiguous and typically are not decided until after a device is approved (Krucoff, 
Brindis, Hodgson, Mack, & Holmes, 2012). Overall, the potential for insurance coverage and 
reimbursements impacts the level of innovation involved with updating a current device or 








 The last barrier to innovation mentioned in Table 2 is patenting. Patents are both an 
incentive and a barrier to innovation in the medical device industry. The incentive with patents is 
clear as a company will obtain exclusive rights to their product and can increase prices without 
competition. The barrier occurs when large companies cover their products with general patents. 
This makes it more difficult for smaller companies to enter the market and discourages 
innovation in that field (Bergsland, Elle, & Fosse, 2014). Kahn (1991) noted a difference 
between patents in the pharmaceutical industry versus the medical device industry. He stated that 
pharmaceutical patents are less of a barrier as the basic principle of a drug is not patentable but 
rather the drug itself. An example he provides is that the use of antihistamines to treat allergies is 
not patentable, but the specific molecule configuration is. In contrast, patents in the medical 
device industry tend to focus on the principle of the product, not the particular technology or 
device (Kahn, 1991). Overall, the patenting approach in the medical device industry discourages 
innovation. 
Innovation during COVID-19  
 The first part of this literature review shows that there are multiple factors that inhibit 
innovation in the medical device industry. The COVID-19 pandemic has had a unique effect on 
the ventilator industry. Ventilators are typically large, complex, expensive devices that are used 
in intensive care units. The impact of COVID-19 on respiratory systems has created a dire need 
for increased ventilator inventory worldwide. The only feasible way to fulfill this order is to 
remove or reduce the barriers to innovation mentioned above. Due to the novel nature of 
COVID-19, there are only a few published articles about innovation during COVID-19. The 




These articles can be seen in Table 3. The literature analyzes the effect of the pandemic on 
technology, innovation, and lessons learned. Overall, the pandemic sparked various innovative 
responses and provided learning opportunities for the medical device industry. 
Table 3: Summary of articles on innovation during COVID-19  
Author Purpose Conclusion 
(Brem, 2020) 
Analyze the effects of the 
worldwide pandemic on 
technology. 
The pandemic forced the 
widespread adoption of 
existing technologies. 
(Chesbrough, 2020) 
Discuss managing innovation 
and lessons learned. 
Openness speeds up the 
innovation process. 
(Farrugia & Plutowski, 
2020) 
Discuss innovative lessons 
from COVID-19. 
Emergence of enhanced 
digital care options. 
(Harris, Bhatti, Buckley, & 
Sharma, 2020) 
Review of frugal innovation 
measures in response to 
COVID-19. 
Necessity drives innovation 
and resourcefulness shines in 
times of crisis. 
(Lee & Trimi, 2020) 
Presents convergence 
innovation as a catalyst for 
managing COVID-19. 
Many solutions would not be 
possible without convergence 
of different ideas. 
(Morton, 2020) 
Describe incentives for 
innovation normally versus in 
a pandemic. 
COVID-19 provided 
incentives to create cheaper 
ventilators. 
(Mulligan, 2020) 
Quantify economic sacrifices 
and how to reduce the 
economic burden. 
Medical innovation can 
reduce the intensity of 
COVID-19, reducing the 
ultimate economic impact. 
(Von Krogh, Kucukkeles, & 
Ben-Menahem, 2020) 
Present an altered approach to 
innovation and lessons 
learned. 
Innovation based on 




innovations and how they 
will last past COVID-19. 
Multiple innovations will be 
promising for use past 
COVID-19. 
 
 The first thing the COVID-19 literature revealed was the range of innovation types 
between the articles. Innovation is a term that can be applied in different ways based on the topic 
of interest. Differences in types lie in what technologies, ideas, and resources are used and how 




reviewed on COVID-19 innovation are stated in Table 4. Even though there may be different 
aspects of each type, they all promote a new or improved product as a result. 
This research paper’s definition of innovation is a change that occurred whether it is due 
to the intended use, product design, or product development. The change in the product must 
have a degree of novelty and usefulness to the ventilator industry. 
Table 4: Innovation types and descriptions from literature review articles 
Author Type Description 
(Chesbrough, 2020) Open 
“a distributed innovation process involving purposive 
knowledge flows across organizational boundaries for 
monetary or non-monetary reasons” 
(Harris, Bhatti, 
Buckley, & Sharma, 
2020) 
Frugal 
“doing more, with less, and being creative, 
innovative, and resourceful in the face of institutional 
voids and resource constraints” 
(Lee & Trimi, 2020) Convergence 
“deployment of new ideas and/or technologies in 
fundamentally different ways to create new or 
additional value for continued success of the 





“innovation centered on repurposing of readily 
available ideas, knowledge, and technologies” 
(Brem, 2020) General 
“technologies that have evolved as a result of the 
pandemic, which may result in the development of 
new and practical solutions to current and future 
problems” 
 
Most of the articles found around COVID-19 innovation discussed what lessons have 
been learned. Table 5 categorizes the lessons learned from each article. The most common ones 
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Collaboration   
 Collaboration was identified as a lesson learned in innovation by all the articles reviewed. 
This idea was mentioned in various ways, including general collaboration, government 
collaboration, open communication, and mapping of resources and technology. Countless 
COVID-19 solutions have stemmed from some sort of collaboration, whether it be cross-
sectorial, cross-disciplinary, international, or governmental. These collaborations have fostered 
innovation as industries quickly shifted their goals to find solutions to one common problem 
(Brem, 2020). Partnerships between seemingly unrelated industries have allowed for various 
types of contributions; while one partner may be the device expert, another may provide the 
financial capability, and another may have the manufacturing space and personnel to scale up 
production rapidly. One example of this type of partnership is medical device companies 
partnering with car manufacturers. The medical company has the expertise and regulatory 
experience to produce a ventilator quickly. Still, their manufacturing spaces are typically smaller 
scale as they do not need large amounts of their product made (Farrugia & Plutowski, 2020). The 




quicker relief for future pandemics as well. Companies have been able to build relationships that 
they may not have built otherwise. This experience has shown the significant solutions that can 
come to fruition when there is a common goal in mind. Another type of collaboration specifically 
mentioned was government collaboration. The government has made some temporary 
modifications to its policies to allow COVID-19 solutions to enter the market quickly. One 
method the government uses to complete this is public-private partnerships. Additionally, there 
have been some measures to increase flexibility in the regulatory processes for areas such as 
clinical testing, medical devices, and the use of virtual care such as telehealth (Farrugia & 
Plutowski, 2020).  
 Intentional communication is another skill that innovators utilized during COVID-19. 
The end-users of many COVID-19 solutions are patients and physicians. Groups working on 
various solutions emphasized the importance of incorporating the end-user into the design 
process as soon as possible. Usability studies are a common practice used in product 
development to gain a better understanding of how users will interact with their devices. This is 
especially important when creating medical devices. Intuitive medical devices provide much less 
of a safety risk than devices with many similar buttons and confusing alarm signals. 
Incorporating physicians in the early stages of product design allows innovative groups to design 
specifically for the end-user. Additionally, physicians may also be a great source of innovative 
ideas (Chesbrough, 2020). Generally, no one understands the importance of a design better than 
the end-users themselves, and it is the engineer’s job to build a device that fits their needs as 
closely as possible. Communicating setbacks in design or production openly is another way to 
expedite innovation (Von Krogh, Kucukkeles, & Ben-Menahem, 2020). If a firm or individual 




already found a solution to this problem. In a time of crisis, there is not enough time for people 
to sit and figure out problems independently. The most productive way to innovate rapidly is to 
communicate with others and integrate suggested solutions. 
 The last section relating to collaboration is mapping resources and technology to build a 
network of knowledge. Lee and Trimi (2020) state that collective intelligence is required to 
achieve a common goal. An effective way to collect knowledge is to make an inventory of 
existing resources. This can include capable facilities, databases, software, existing products, 
talent, and expertise (Von Krogh, Kucukkeles, & Ben-Menahem, 2020). Everything that an 
individual can think of that may be remotely helpful should be added to this web of knowledge. 
Creating these large networks encourages collaboration in problem-solving as there are many 
different avenues people take to develop products. There is no specific process that is better than 
another, especially in a time of crisis (Farrugia & Plutowski, 2020). Collaboration between firms, 
individuals, and universities, has undoubtedly had the largest impact on the sheer number of 
innovative solutions developed in record time for COVID-19. 
Technology Use and Resourcefulness 
 While collaboration has had an undeniable impact on the production of innovative 
solutions, many of these solutions would not have been possible without the use of emerging 
technology or innovative ways of using current technology. As mentioned in the earlier part of 
the literature review, one barrier to innovation is the hesitancy of the medical device industry to 
incorporate devices with drastic changes in technology. It is more difficult to file for regulatory 





In light of this pandemic and the scarcity of previously available solutions, companies 
have been pushed to incorporate technology that they may have been reluctant to adopt in the 
past (Brem, 2020). Some of this technology includes the use of artificial intelligence (AI) and 
machine learning. These options were quickly incorporated in the medical device industry to 
help identify specific biological components that may help vaccine development or identify 
between non-COVID-19 patients and COVID-19 patients based on their lung scans (Farrugia & 
Plutowski, 2020). Another result of machine learning during COVID-19 was a machine that 
could pair solutions with problems that have been shared in an open database (Von Krogh, 
Kucukkeles, & Ben-Menahem, 2020). The use of emerging or new technology has shown to be 
helpful in the production of innovative solutions, but resourcefulness has an impact as well.  
Due to the supply chain issues caused by COVID-19, firms are thinking about product 
development in a distinct way. They are trying to work with what they already have whether that 
is using byproducts from their other products or using their existing facilities to their advantage. 
This shift in innovation has been shown by the efforts of cosmetic companies and distilleries to 
convert their sterile manufacturing systems to produce hand sanitizer (Von Krogh, Kucukkeles, 
& Ben-Menahem, 2020). Resourcefulness is a more sustainable solution to innovation and 




Literature Review Summary 
 The major barriers to innovation cited in the literature were brought on by the 
unpredictability and the cost of the regulatory process. COVID-19 has ignited a spark in 
innovative medical devices and shown that there are feasible solutions to managing these 
barriers. Some notable qualities of innovative efforts during COVID-19 have been the increase in 
collaboration and the unique use of existing technology and resources. The pandemic provided a 
common goal for people to work towards which increased the use of partnerships. Since 
COVID-19 is a new disease, the literature on this topic is limited. The articles included in this 
literature review were only able to analyze a few products and examples. From the information 
gathered here, this thesis aims to build on the ideas established in these articles. This will be 












 The main purpose of this thesis is to determine the impact of the EUA on ventilator 
innovation during COVID-19. The literature review suggests that there are challenges that exist 
that impede medical device innovation, including challenges presented by the 510(k) pathway. 
Times of crisis often result in innovative solutions and the EUA presents companies with a 
unique opportunity to rapidly bring these solutions to the public. While the EUA is a temporary 
authorization, it provides a framework with reduced regulatory barriers. To determine the impact 
of the EUA on ventilator innovation, this thesis will conduct a qualitative assessment in an 
attempt to answer the following research question: 
What level and types of innovation did the COVID-19 EUA for ventilators generate? 
 This research question will be studied from various angles to provide a complete analysis. 
First, 510(k) data will be analyzed to understand historical patterns of the ventilator industry. 
Next, the EUA data will be analyzed to identify the types of organizations and ventilators that 
obtained authorization. Finally, individual EUA ventilator designs and development processes 
will be analyzed in depth to identify how and where innovation occurred. 








 This paper will conduct a qualitative assessment to analyze public statements about the 
nature of ventilator innovation generated by the COVID-19 EUA. I did this by using publicly 
available data from the FDA website, Nexis Uni, company web pages, product brochures, and 
Google. The use of available data and press releases was the most practical research design given 
the novel nature of COVID-19 and limitations such as lack of access to EUA applications, 
impracticality of interviewing with strained medical industry professionals due to COVID-19, 
and the short timeline for thesis completion.  
Data Collection 
 Initial data collection consisted of gathering information from the FDA. First, I 
downloaded the releasable 510(k)s from 1976 to August 2020 from the “Downloadable 510(k) 
Files” on the FDA website. Next, I collected EUA ventilator information from “Appendix B: 
Authorized Ventilators, Ventilator Tubing Connectors, and Ventilator Accessories” from the 
COVID-19 Emergency Use Authorizations for Medical Devices. Information was collected for 
devices authorized between March 24th, 2020 and August 30th, 2020. EUA device information 
from the FDA was limited, which led to additional data collection through Nexis Uni, company 
web pages, product brochures, and Google.  
 Nexis Uni is an academic search engine that can search through various resources such as 
the news. An advanced search was completed in Nexis using various combinations of the 
following terms to obtain appropriate results: [company name], [device name], [EUA], [COVID-
19], and [ventilator]. News articles did not provide consistent information across companies and 




Nexis data. The following information was investigated from company web pages based on 
available information: [EUA device], [press releases], and [COVID-19 response]. The sources 
used for each of the EUA products are in Appendix 4: Nexis Uni, Company Web Pages, and 
Google Sources. 
Data Analysis 
510(k) Downloadable Files 
 The information obtained from the files includes the 510(k) number, applicant, contact, 
address, device name, date received, decision date, decision, advisory committee, product code, 
type of submission, class designation, and review information. For this thesis, the following 
categories were of focus: applicant, date received, decision date, and product code. The first step 
I took was to filter the data for ventilator product codes that are currently marketed in the US, 
these codes are listed in Table 6 (FDA EUA COVID-19, 2020). Next, I analyzed this data in 
Tableau to visualize product approvals over time and the distribution of product codes prior to 


















BSZ Gas-Machine, Anesthesia II Y 
BTL Ventilator, Emergency, Powered (Resuscitator) II Y 
BZD Ventilator, Non-Continuous (Respirator) II - 
CBK Ventilator, Continuous, Facility Use II Y 
MNS Ventilator, Continuous, Non-Life Supporting II - 
MNT 
Ventilator, Continuous, Minimal Ventilatory Support, 
Facility Use 
II Y 
NFB Conserver, Oxygen II - 
NHJ Device Positive Pressure Breathing, Intermittent II - 
NHK Resuscitator, Manual, Non-Self-Inflating II Y 
NOU Continuous, Ventilator, Home Use II Y 
NQY 
Ventilator, Continuous, Minimal Ventilatory Support, 
Home Use 
II Y 
ONZ Mechanical Ventilator II - 
QAV 





 There are two major types of ventilators, invasive and noninvasive. The basic 
components of an invasive ventilator can be seen in Figure 1. These consist of the ventilator, 
filters, expiratory and inspiratory limbs, a humidifier, and the endotracheal tube (Berlinski, 
2017). 
 




 The basic components of a noninvasive ventilator can be seen in Figure 2. These consist 
of the ventilator, inspiratory limb, expiratory limb or leak, humidifier, and a face mask 
(Berlinski, 2017). 
 
Figure 2: Diagrams of basic noninvasive ventilators. Top: dual-limb circuit. Bottom: single-limb circuit. (Berlinski, 2017) 
 Table 6 highlights the ventilator codes that are most prominent throughout this thesis. 
These product codes are BSZ, BTL, BZD, CBK, and MNT. BSZ is an anesthesia machine that is 
typically used during surgery. These devices can be used without anesthesia settings in 
emergency situations such as COVID-19 to act as a normal invasive ventilator. BTL is a 
powered emergency ventilator. These devices are typically compact and more simple to use, 
making them commonly used in ambulances or in the field. BZD is a noninvasive respirator 
device. This can be a variety of Positive Airway Pressure (PAP) machines such as continuous 
(CPAP) and bilevel (BPAP). CPAP devices provide a continuous level of pressure while BPAP 
devices can provide varying levels of pressure. BZD devices are typically used at home to treat 
respiratory conditions such as obstructive sleep apnea. CBK is the typical invasive ventilator 




typically double coded with BZD and CBK products and can be used in a hospital or at home 
and invasively or noninvasively.  
EUA Company Characteristics 
Data collected from the FDA “Ventilators and Ventilator Accessories EUAs” webpage 
provided information on the date of authorization, manufacturer, product name, and device 
description. Since the EUA only provided device descriptions, not product codes, I assigned 
product codes to match the descriptions seen in the table above. Once product codes were 
assigned, authorizations over time and the distribution of product codes were visualized in 
Tableau. Additionally, I coded the data collected based on the categories in Table 7 to gain a 
better understanding of companies that obtained EUA authorization. 
Table 7: EUA authorized ventilators coding key 
Variable Code Description 
Product Code Table 6 See table 
Previous 510(k) Approvals 
0 
No results in the 510(k) database 
Search: [Company] 
1 
Results in the 510(k) database 
Search: [Company] 
If no prior 510(k), was the 





0 Non-medical device industry 
1 Medical device industry 
Company Origin 
0 Not U.S. based 
1 U.S. based 
New Player 
0 
Yes, company is not contained in the 
downloadable 510(k) files 
1 




Organization existing prior to COVID-19 
concerns 
1 
Organization that appears to have been created 





Detailed EUA Ventilator Analysis 
 Using the data gathered from Nexis, company web pages, product brochures, and Google, 
I completed a detailed analysis of each ventilator on the EUA list. This data was utilized to 
identify information about unique properties of EUA products such as design, components, or 
supply as well as similarities and differences in product designs. While data was collected, I 
separated it into categories to allow for easy identification of themes. Some of the key categories 
analyzed are listed in Table 8. 
Table 8: Nexis and company webpage data categories 
Categories Description 
Product existence prior to 
the EUA 
Did the product exist prior to the EUA?  
If yes, when was it developed? What is its intended use? Were any 
modifications made? 
Plans to pursue full FDA 
approval 
Did the company mention plans to pursue FDA approval once the 
EUA is invalid? What are the plans? 
Product Development 
Timeline 
How long did the product take to develop? 
Design Goals What design goals did companies explicitly state? 
Components 
What components did the company explicitly point out as unique or 
innovative? 
Technology 
What technology did the company explicitly point out as unique or 
innovative? 
Manufacturing 
Did the company explicitly point out unique or innovative 
manufacturing measures? 
Supply Chain 
What supply chain aspects did the company explicitly point out as 
unique or innovative? 
Open Source Was the design open source? 
Cost 
How much did the product cost to build and/or how much will it 
sell for? 
Partnerships 
Did the company partner with anyone?  
If yes, what was the partner’s contribution? 
Notable Quotes 
Any notable quotes about innovation during COVID-19 or 





FDA Approvals and EUA Authorizations Over Time 
 This section will use the information obtained from the 510(k) releasable database and 
the EUA authorized ventilators, to construct visuals to show approvals and authorizations over 
time. Figure 3 shows the number of 510(k) submissions per year from 1976 to August 2020 that 
resulted in an approved device. There is an overall increase in submissions from 1976 to 1986, a 
stagnant period from 1986 to 2001, another rise from 2001 to 2012, then a drastic drop in 
submissions from 2012 to 2020. There were 51 submissions in 2012, 10 submissions in 2019, 
and 2 from January to August 2020. Submissions per year show a variable pattern with 
alternating increases and decreases. Overall, submissions have shown an increasing trend, but the 






Figure 3: Number of 510(k) submissions per year from 1976 to August 2020. The dark gray line is the sum of the individual 
product codes. 
Figure 4, shows the number of EUA authorizations per week from March 24th, 2020, 
when the EUA was enacted, to August 23rd, 2020, when initial data collection for this thesis was 
completed. Figure 4 shows the largest number of authorizations over the first 7 weeks, March 
24nd to May 3rd. By May 10th, the number of authorizations decreased, this decrease remained 
consistent through the end of the figure. There were a total of 77 authorizations over five months, 
with 57 in the first two versus 20 over the following three months. Comparing Figure 3 and 
Figure 4, 77 devices were approved through the EUA over five months versus 62 510(k) 





Figure 4: Number of EUA authorizations per week from March 24th, 2020 to August 23rd, 2020 
 510(k) and EUA Product Code Distributions 
This section utilized the 510(k) releasable data along with EUA data obtained from the 
FDA to analyze the focus in product codes before versus during the EUA. These distributions 
can be seen in Figure 5. The most common ventilator products prior to COVID-19 were CBK, 
BZD, and BSZ. These products made up 35.52 %, 31.04 %, and 13.66% of the approved 
products from 1976 to August 2020, respectively. The most common products authorized for the 
COVID-19 EUA were BTL – 37.66%, MNT – 28.57%, and CBK – 11.69%. The rise of the 
MNT product code was large as this code only accounted for 1.42% of the products from the 
510(k) database. As you may recall, BTL (ventilator, emergency, powered resuscitator), BSZ 
(gas-machine, anesthesia), BZD (ventilator, non-continuous respirator), CBK (ventilator, 









   






EUA Company Make-up  
This section shows the make-up of the companies that submitted EUA approvals. This 
information can be seen in Figure 6. The three categories in this figure are New Organization – 
organizations that appear to have been created after the increase in COVID-19 concern, New 
Player – a pre-existing non-medical device organization (i.e., NASA, Fitbit, Virgin Orbit), and 
Old Player – a pre-existing medical device company. There were 10 new organizations, 8 new 
players, and 38 old players. 33 of the old players produced ventilator or respiratory related 
products prior to the EUA. New organizations and players mostly submitted emergency 





Figure 6: EUA company make-up with product code distribution 
Pre-existing Devices Overview 
 The purpose of this section is to provide an overview of the devices on the EUA list that 
existed prior to the EUA. This information was determined by searching the device in the 510(k) 
database and on the company’s webpage. The full list of EUA products can be found in 
Appendix 1: EUA Products. Additionally, there were 10 devices for which no data was found 




Appendix 2: Products with No Data Found and Appendix 3: Repeat Devices. For further 
analysis, the 10 devices with no data and the 5 device repeats were removed from the ventilator 
count leaving 62 products.  
 Table 9 shows four products that were on the market prior to the EUA, that did not make 
any modifications to their devices for EUA authorization, and the intended use did not change. 
These devices were utilized in other countries and did not have 510(k) approval. The EUA 
authorized the device to be used in the U.S.  




What is the 
Intended Use? 
Product Code 











Atlan A350 and Atlan A350 
XL 









 Table 10 shows 12 devices that existed prior to COVID-19 and no modifications were 
made to the device, but the intended use of the device changed for the EUA. This information 
was determined by the data collected from company web pages. Seven of these devices were 
approved in other countries and do not have 510(k) approval. One of these include the Luna G3 
B30VT by 3B medical; attorney Gunawardhana, who helped 3B medical obtain authorization, 
noted that “it is deeply rewarding to see a client with innovative thinking gain approval to help 
with an issue that has become all too real for Americans” (Shook Hardy & Bacon, 2020, p. 1). 
The other five devices do have 510(k) approval but the EUA was necessary to allow the devices 
to be used to treat COVID-19 patients. The intended use for most of the devices is supportive 
devices for people with restrictive lung disorders or obstructive sleep apnea (OSA). These types 













VPAP ST  
Yes 
Restrictive Lung Disorders, 
Severe COPD, Hypoventilation 
BiLevel Therapy  
MNT 









BiLevel Therapy  
MNT 
BMC Medical  Y-30T No 
OSA/ respiratory insufficiency 
BPAP system 
MNT 











Restrictive Lung Disorders, 
Severe COPD, Hypoventilation 
BiLevel Therapy  
MNT 

















No PAP system BZD 
Shenzhen Yamind 
Medical Tech 
DM series No CPAP system BZD 
SysMed (China)  VM series No PAP system MNT 
 
Table 11 shows eight devices that existed prior to the EUA and contain modifications that 
were made for COVID-19. These products were grouped in this table if an article from Nexis or 
a company webpage explicitly stated that a modification was made to the device for COVID-19. 
Modifications made to devices include the use of alternate components, maximizing efficiency, 
modifying a device such as a CPAP into a ventilator, and adding a closed-circuit design with a 








Table 11: EUA devices with modifications 
Company Product Modification Product Code 
VenTec Life Systems 
V+Pro Emergency 
Ventilator 




Hillrom MetaNeb 4 
Modified to a closed-
circuit design using a 





AutoMedX SAVe II Series Ventilator 
Made performance 
modifications to 
maximize efficiency for 
COVID-19 
BTL 
Wilcox Industries Corp 
Wilcox PATRIOT SAVR 
(Amended July 21, 2020) 
Modified for COVID-
19, previous was a 
large backpack, 
redesigned to make it 
smaller and more 
portable 
BTL 
Somnetics International Transcend 3 BiPAP 
Repurposed CPAP into 
BiPAP machines 
BZD 
NeoNatal Rescue AdultLife Pro Ventilator 
Modified their infant 
ventilator for adult use 
BTL 
Breas Medical Z2 Bilevel 




Life 2000 Ventilation 
System Product No. BT-
V5 
Modified a noninvasive 
device for invasive use 
CBK 
 
Detailed EUA Ventilator Findings 
 This section utilizes data collected from Nexis, company web pages, product brochures, 
and Google to provide a comprehensive summary of notable findings. First, the overall design 
goals are analyzed. Next, areas where innovation occurred were analyzed further, such as supply 
chain, manufacturing, and unique components as well as whether the innovative measure was 






This section provides a summary of the design goals identified by companies. Design 
goals between companies were similar. The most common goals were: 
• Portable 
• Affordable 
• Simple to use 
• Easy to maintain 
• Minimal components 
• Easy to manufacture 
These goals were determined in response to the situation imposed by COVID-19. Some 
of the goals revolve around the usability of the device. An example of this is from AutoMedX 
who stated, “the idea was to make something simple that could be easily deployed by medics in 
high-stress environments” (AutoMedX, 2020). The other goals revolve around designing a 
simple device that allows for rapid, large scale production. Philips is a company that had 
ventilators on the market prior to COVID-19, but they created a new ventilator for the EUA that 
was “designed for mass production” (Philips, 2020). The design goals identified relate to the 
sources of innovation that will be explained in the next section. 
Innovation Findings Summary 
 An overview of sources of innovation and innovative solutions can be seen in Figure 7. 
There were four main sources of innovation identified in this paper, intended use, supply chain, 
manufacturing, and components/ technology. The devices that fall under intended use are 
identified in Table 10. Various PAP machines altered their intended use definition to treat 
COVID-19 patients. There were 17 companies that mention innovation in the supply chain, 15 in 
manufacturing, and 45 in components and technology. The detailed findings from these branches 





Figure 7: Summary of innovative solutions as identified in publicly available information. The dark blue arrows represent 
company count. Colored arrows represent product count. Products can appear more than once so numbers under individual 
branches may not add up to the root branch. 
Components and Technology 
 The component and technology innovations were split into two categories based on the 
nature of the innovation. The first category are features that were used in ventilators before the 
EUA, but the products below added them to their design, this can be seen in Figure 8. The 
second category, seen in Figure 9, are features that are less common or unique to the ventilator 
industry.  
Two of the most common components that were emphasized in EUA devices were the 
addition of certain filters to breathing circuits such as high-efficiency particulate air (HEPA) 
filters and the ability for the device to be powered by a battery. Four companies mentioned the 




an “innovative expiration valve disassembling concept that brings more ease and efficiency to 
the sterilization process” (Lanick, n.d.). 
 
Figure 8: Features added to EUA products. Products in italics were developed by a new organization or player. 
Figure 9 shows the products that implemented newer technology and solutions in their 
EUA devices. The first set of technology is remote access. Six devices mention the 
implementation of a remote access system, two of them stem from a new organization or player. 
Remote access was implemented differently in each device including the use of a removable 
tablet, remote control, and Wi-Fi access. ResMed mentioned that they had big plans in digital 
health prior to COVID-19 and the pandemic brought some of their innovations to surface earlier 
than expected (ResMed, 2020). Four products focused on software to enhance the usability of the 
device. These ranged from incorporating artificial intelligence (AI) to programmable computer 
logic that enables the device to self-calibrate. Two products used innovative air processing 
technologies. Vayu created an innovative air blender that does not require a compressed air tank, 
Filter (type)
• Y-30T
• Luna BPAP 25A
• pNeuton (bacterial)
• E30 (bacterial / viral)
• SAVe II (HME / 
bacterial)
• Luna G3 BPAP


















• Puritan Bennet 560
• SAVe II Series
• JIXI H-100





•VG70 (metal exhalation 
valve)
•SV Series (inspiration 
valve)
•Lyra x1 (expiration valve)





they perceive their device as “an ultra-low cost, disruptive innovation to address the world’s 
most pressing health challenge” (Vayu, 2020). Not only was Vayu’s solution innovative, but the 
approach they took was unique as well. Vayu designed their bCPAP device as a neonatal 
solution because 80% of the ventilators utilized in the NICU are full-service ventilators. With 
this solution, these full-service ventilators can be used to treat adults with COVID-19 (Vayu, 
2020). Two devices took a modular approach to their design, which allows parts to be swapped 
based on availability and location of use. Finally, ten products pursued an automated bag valve 
mask (BVM) design, these were all made by new players and organizations. BVM’s were also 
used as a response to supply chain innovation. 
 
 













•nHale BiPAP: AI, intelligent 
factory control (IFC)
•X-Vent: programmable 
computer logic (PLC), self-
calibrating 
•MVM: focus on software, kept 
hardware minimal
•Model 6000S, T5, T7: 














• MVM: modular design allows parts to be 
swapped
•CoroVent: electricity type, gas 
connections, and language can be 
modified for areas around the world
Air Processing Technology
• Vayu bCPAP: innovative air blender





 Some aspects of EUA products that are innovative stem from the supply chain, including 
how and where components are sourced. Most of the innovation in the supply chain took place 
with new organizations and players. 
 Table 12 shows unique supply chain features that were mentioned by new organizations 
and players. New organizations and players were the only ones that sourced bag valve masks 
(BVM) for their products, there were 10 products that did this. These companies chose to utilize 
a component that would be readily available in a hospital due to the equipment shortage from 
COVID-19. Virgin Orbit is one of these companies and stated the importance of “sharing ideas 
across a broad national and international network to accelerate progress on solutions to this 
equipment shortage” (Virgin Orbit, 2020, p. 1). Two of the companies utilized components that 
can be made with do-it-yourself (DIY) techniques such as 3D-printing, metal stamping, and 
modifying consumer goods. Another common method used to source materials was the use of off 













Table 12: Supply chain features of new organizations and players 
Company Classification Product Supply Chain 




Spiro Devices New Organization Spiro Wave BVM 
Air Boost New Organization AustinP51 BVM 
Venti-Now New Organization Venti-Now Resuscitator 





New Organization WorldVent Ventilator 
Design based on common 
consumer electronics  
Key components have 
multiple sources. 




MICo Medical New Organization  CoroVent EU sourced components 
PVA New Player PREVENT 
PVA makes every 







Coventor Adult Manual 
Resuscitator Compressor 
frame can be metal-
stamped, 3D printed, or 
modified consumer goods 
BVM 




Fitbit New Player Fitbit Flow BVM 
Stewart & Stevenson 
Healthcare  
New Player Apollo ABVM 
DIY Components 
BVM 
NASA Jet Propulsion 
Laboratory 
New Player VITAL Ventilator 
Utilizes materials outside of 

















Table 13 shows the supply chain features of old players. Old players attempted to combat 
the component shortage by utilizing a partner’s supply network. 
Table 13: Supply chain features of old players 
Company Product Supply Chain 
Covidien 
Puritan Bennett 560 
Ventilator System 





Partner’s supply - Sourced parts and assemblies by utilizing 




Partner’s supply - Sourced parts and assemblies by utilizing 
Flex and Jabil’s supply networks 
 
Manufacturing 
Another way innovation played a part in the production of EUA devices was through 
manufacturing. Innovative manufacturing approaches were split between new organizations and 
players and old players. 
New organizations and players were the only companies that mentioned designing for 
manufacturability. Companies mainly approached this by minimizing components. Spiro 
Devices was one of the companies that took this approach, “like so many other measures granted 
EUA, this may not be an ideal replacement for FDA-approved equipment, but it’s an innovative, 
scalable solution that could mean big differences in the level of care at overburdened healthcare 
facilities” (Etherington, 2020, p. 1). Other approaches included redesigning an existing 









Table 14: Manufacturing features of new organizations and players 











Design for manufacturability - 
low component counts and 
minimal dynamic performance 
requirements  
PVA New Player PREVENT 









Partner - Boston Scientific 
Virgin Orbit New Player 
Virgin Orbit 
Resuscitator 












Design for manufacturability - 
reduced number of parts 
Nanotronics 
Imaging 
New Player nHale BiPAP 
Innovative manufacturing 
vision to quickly build and 
scale the device 
 
The main approach old players took was to utilize partnerships. Some partnerships 
occurred between a medical device company and a non-medical device company such as VenTec 
Life Systems and General Motors (GM) or GE healthcare and Ford. VenTec Life Systems stated, 
“this partnership is a historic effort and a great reminder of what can be accomplished with the 
power of American innovation and American manufacturing skill uniting together around a 
singular mission to save lives” (VenTec Life Systems, 2020). Additionally, companies reworked 
typical work routines. Dragerwerk commented on the approach they took, “We have agreed with 
our employees on innovative work organization and working time models. This gives us the 
necessary flexibility to respond to the high volume of orders” (Drager, 2020). Table 15 




Table 15: Manufacturing features of old players 
Company Product Manufacturing 
Vyaire Medical 
LTV2 model 2200 and LTV 
model 2150 
Partner - Spirit Aerosystems 
Inovytec Ventway Sparrow 
Converted part of their missile 
production line 
GE Healthcare pNeuton Model A-E Ventilator Partner - Ford 
Covidien 
Puritan Bennett 560 Ventilator 
System 
Partners - Baylis Medical, Foxconn 
Technology Group, and Vingroup 
MEKICS MTV1000 ventilator Partner - Biolase 
VenTec Life 
Systems 
V+Pro Emergency Ventilator 
Partner - GM  
Redesigned production line 
GM redesigned their manufacturing 
process 
Dragerwerk Evita and Babylog Devices Innovative working time models 
 
Partnerships and Collaboration 
Partnerships were another tool that was utilized for many EUA devices that helped drive 
the innovative measures mentioned above. Table 16 and Table 17 show partnerships where 
specific contributions were mentioned. There were other companies that mentioned partnerships 
but did not comment on who the partner was and/or how they contributed to product 
development. Figure 10, shows an overview of the various types of partnerships and 
collaborations that occurred for the EUA. In the sections above, partnerships were mentioned as 
a source of innovation in the supply chain and manufacturing branches. There were also 
partnerships that helped with design, testing, and FDA facilitation. Partnerships ranged from 
aerosystems, automobile companies, government, universities, hospitals, doctors, and even 
patients. FDA commissioner Stephen Han stated “fighting the virus and treating patients during 
this unprecedented global pandemic requires innovative approaches and action. It also takes an 
all-hands-on-deck approach, [NASA’s VITAL device] shows what we can do when everyone 




collaboration and the importance of interdisciplinary collaboration to spark innovation. Fitbit 
stated that their device “is a great example of the incredible innovation that emerges when 
academia and industry employ problem-based innovation to respond quickly to an important 
need” (Fitbit, 2020). LifeMech was also surprised by the innovation spurred by COVID-19, “it’s 
interesting how this cross-platform collaboration, from people who have never really designed or 
worked on a medical device, leads to something innovative. I think this goes to prove that there 
are no limits to innovativeness, and you can actually do things differently. So, you've got an 
engineer in Germany working with somebody out of their garage in Northern California, and at 
the end of the day, we would just integrate that data together” (LifeMech, 2020). 
 
 
Figure 10: Partnerships between the original authorized company and other industries and how those industries contributed. The 





Table 16 shows the types of partnerships new organizations and players utilized. Seven 
out of nine of these companies worked with someone who was able to help with the design of the 
device. Partnerships for manufacturing, supply, funding, and distribution were also utilized.  
Table 16: Partnerships utilized by new organizations and new players 











2 BME students from University of 
Cincinnati 
UC Health, Cincinnati Children’s 






Medical professionals - critical care 
physicians, respiratory therapists  
Schneider Electric, Casco Systems, 
Border States Electric 












Several Czech companies 









































Table 17 shows partnerships utilized by old players. Ten out of twelve old players 
partnered with another company for manufacturing assistance. Others used partnerships for 
design, funding, supply, distribution, and EUA assistance.  
Table 17: Partnerships utilized by old players 
Company Partner Contribution 




Government, Health Authorities, Hospitals, 
Physicians, and Patients 
Design 
Inovytec 
Directorate of Production and Procurement, 
Directorate of Defense Research and Development 















PCBA board source 
Subassembly production 





General Motors Manufacturing 
Philips Respironics Flex (Trilogy) and Jabil (V60) Manufacturing 
3B Medical Attorney Sonali Gunawardhana  EUA assistance 
AutoMedX NCA Manufacturing 
NeoNatal Rescue 
ATL 















 This section provides additional information that was found during data collection. The 
information includes the cost of the EUA devices, open-source designs, and plans to pursue full 
FDA approval. 
EUA Product Costs 
Product cost was not available publicly for many of the products, but some products 
mentioned price ranges or estimated cost in reference to a traditional ventilator. A traditional 
ventilator costs between $25,000 - $50,000, this estimation was supported by multiple articles 
throughout the analysis (Glass, 2019). Table 18 shows some products along with their cost. The 
cost of devices varies significantly even within the same product code. The devices submitted by 
new organizations and players generally cost less. One exception goes to Vayu, whose mission is 
to create disruptive healthcare solutions (Vayu, 2020). Vayu’s device has the lowest cost, $120. 
Additionally, old players typically did not mention prices, so there are only three old players in 










Table 18: EUA product cost 










Spiro Wave BTL 
















3x less expensive, 














New Player Coventor BTL 
Cost: $1,000 
Cost to build: $150 
PVA New Player PREVENT BTL 
$6,000 - $8,000 





New Player Apollo ABVM BTL Target price is under $250 
Beijing 
Aeonmed 
Old Player VG70 ventilator 
Critical Care 
Ventilator 
Original Cost: ~ $50,000 
EUA Cost: $12,000 - $17,000 









CPAP Cost to build: Less than $120 
 
Open-Source Designs  
Another solution that appeared multiple times was the use of open-source designs. Table 
19 below shows the EUA authorized open-source designs. All five of the open-source designs 






Table 19: Open-source designs 





University of Minnesota Medical 
School 
New Player 
Coventor Adult Manual Resuscitator 
Compressor 
NASA Jet Propulsion Laboratory New Player VITAL Ventilator 
Elemaster S.p.S. Technologie 
Elettroniche 
New Player 
Mechanical Ventilator Milano 
(MVM) 
Stewart & Stevenson Healthcare New Player Apollo ABVM 
 
Plans to Pursue FDA Approval 
Lastly, data was collected on companies’ plans to obtain full FDA approval, which would 
allow their device to stay on the market after the COVID-19 EUA is withdrawn. There are nine 
devices that plan to get full FDA approval, these devices can be seen in Table 20. Three of these 
devices existed prior to the EUA. One company did not have FDA approval on their device in 
the U.S. The other two companies are pursuing approval for modifications they made for 
COVID-19. Wilcox Industries did not explicitly state that they were pursuing full approval, but 
they did get a patent on their modified device which may infer they have plans for it to be 
approved. NeoNatal Rescue modified their neonatal ventilator to be used for adults and they plan 
to pursue approval for their new AdultLife Pro ventilator. Additionally, there are six companies 
with new devices that stated they are interested in or have already started the regulatory process. 
Three of these utilized BVMs in their designs and the other three created compact emergency 
ventilator designs. Eight out of the nine devices in Table 20 fall under the emergency ventilator 






Table 20: EUA products planning to pursue FDA approval 




































BTL Yes Yes 


















No but was 
modified 
for EUA. 
Not stated but a patent was 




























 This section will start by discussing the results obtained from the releasable 510(k) 
database. Next, an overview of the EUA results will be compared to the 510(k) results to identify 
the result of decreased regulatory barriers from the EUA on product submissions and types of 
ventilators produced. Finally, detailed EUA findings and the nature of innovation will be 
explained. 
Ventilator Product Approvals Over Time 
 The results from FDA approvals and EUA authorizations showed a notable drop in 
510(k) product submissions from 2012 to 2020. There are too many variables involved to assign 
a known cause to the drop. For example, it may be that entry into the database by the FDA is 
delayed. It is still worth noting as a possible indication that there was a lack of innovation in 
ventilator technology prior to the pandemic. On the other hand, when the FDA enacted the EUA, 
there were 77 device authorizations within five months, which is equivalent to the 510(k) 
submissions that occurred over the past four to five years. While the EUA authorization is 
temporary and is meant to stimulate new products and intended uses to help a national health 
crisis, this uptick in EUA devices is notable. It signals that regulatory barriers may be one of the 
factors inhibiting innovation. 
Change in Product Code Focus 
 The 510(k) releasable data and products submitted to the EUA showed a change in 
product code focus. Before the EUA, CBK (ventilator, continuous, facility use) and BZD 
(ventilator, non-continuous respirator) were the most common products being developed, making 




ventilator) and MNT (minimal ventilatory support) were the most common, making up 66.23% 
of EUA devices. BTL rose from 7.16% prior to and 37.66% during the EUA. MNT rose from 
1.42% prior to and 28.57% during the EUA. BTL’s increase aligns with what would be expected 
as emergency ventilators are typically less complicated and easier to develop in a time of 
emergency. MNT appeared to rise with the change in the intended use of PAP devices. Most 
COVID-19 patients do not need full ventilatory support, and MNT is a noninvasive option. The 
shift in product code distribution indicates a likely increase in demand for innovation within 
these device categories. 
Additionally, one factor that may have contributed to the shift in focus in product codes is 
the make-up of the companies that submitted devices to the EUA. There were eight new players 
and ten new organizations that submitted devices to the EUA. Seventeen of these companies 
submitted emergency ventilators. If these new players did not enter the industry, then the 
emergency ventilator distribution would have only increased by 8.42% instead of the 30.5% 
increase we saw in the findings. As we saw in the literature review, early-stage innovation 
typically stems from new entries to the market. Innovation tends to increase when new players 
and organizations enter a field because they typically enter to fill a need that has not been met. 
There are no preconceived ideas or processes that may unintentionally limit innovation. In the 
next part of the discussion, I will discuss the motivation for innovation during COVID-19. 
Motivation for Innovation 
 Innovative solutions created in response to COVID-19 were centered around three main 
issues. The first issue is the ventilator supply chain. Typical ventilator components were in short 
supply and shipping delays made it difficult to obtain parts from inside and outside the United 




alternate components over typical ventilator components. Additionally, The EUA for ventilators 
was not enacted until two months after COVID-19 was declared a public health emergency. By 
the time the EUA was enacted, the concerns of a ventilator shortage were high. Because of this, 
companies wanted to produce as many ventilators as they could, as quickly as possible. They did 
this by making their designs simple and easy to build to enhance manufacturability. Lastly, 
companies that designed ventilators for the COVID-19 EUA focused on the usability of the 
devices. Current ICU ventilators are difficult to use, so new designs needed to be as intuitive as 
possible to ensure ease of use for medical personnel. Furthermore, ventilators were designed to 
be portable and affordable to fill the needs of thousands of hospitals throughout the United States 
and internationally. The design goals imposed by the constraints of COVID-19 led companies to 
create innovative ventilators that could rapidly fill these needs. In the next part of the discussion, 
I will go into more detail about how new players and new organizations contributed to 
innovation. 
Innovation from New Organizations and New Players 
New organizations and players (companies that started after the rise in COVID-19 
concern and pre-existing non-medical device companies, respectively) made up 25% of the EUA 
devices and 32% of companies that submitted to the EUA. This makes up a substantial amount 
of the EUA approvals and may indicate that barriers in the medical device industry inhibit new 
entry and, therefore, innovation. Throughout the analysis, some patterns were seen in the 
innovative measures pursued by new organizations and players. These companies had to create 
ventilators in the face of many constraints created by COVID-19. In order for new ventilator 
designs to have a positive contribution, typical supply chains and designs of ventilators needed to 




 As mentioned in the findings, ten of the products incorporated the automation of a 
manual breathing bag. The concept of implementing an automated BVM has been studied before 
in the medical device industry as a solution to combat fatigue in EMS workers and as a realistic 
solution for low-resource hospitals (Williams, 2019). While this design concept has been studied, 
it has not been widely adopted. New organizations and players were the only companies that 
used BVMs in their designs. This approach makes sense because new players probably do not 
have a lot of experience with ventilators and ventilator designs, if any. Automating a BVM can 
be executed quickly and utilizes supplies that are readily available in hospitals. Three of these 
companies are planning to pursue full FDA approval.  
 The other eight products by new players were seven compact emergency ventilator 
designs and one BPAP device. These products, along with the BVM designs, utilized off the 
shelf, globally available, and even 3D printed components. New players needed to be innovative 
with materials used to build the ventilators due to the strained ventilator supply chain. The 
utilization of readily available components was also prominent in open-source designs. All five 
of the open-source designs were created by new organizations and players. The use of readily 
available components allows for these designs to be reproduced more easily by others. These 
designs were all accessible online, allowing anyone to help the crisis. Open-source designs 
facilitate open innovation by allowing knowledge to travel across endless sources for non-
monetary reasons (Chesbrough, 2020). Three other EUA devices that were not open source noted 
that they gained their inspiration from open-source devices. While open-source designs may not 





 In addition to taking a unique supply chain approach, new organizations and players were 
the only companies that intentionally designed their device to increase manufacturability. These 
companies were looking to make their devices as simple as possible so they could be produced 
and distributed rapidly. Companies did this by minimizing components, which was also able to 
help drive the cost of the products down.  
 New players were able to implement various unique component and technology elements 
into their designs. The more common features included in products were the addition of filters to 
the breathing circuit and battery power use. Filters help decrease transmission of the disease, and 
batteries allow devices to be portable, which is crucial when hospitals are over capacity, and 
makeshift hospital set-ups are in use. Five companies integrated newer and novel technologies 
into their design. This ranged from remote access to software features to modular designs. Two 
out of the five companies used modular designs, while the other three chose to focus on 
enhanced software features. The modular designs allow parts to be swapped based on availability 
and location of use, which increases ventilator accessibility. The software innovations allow the 
ventilators to be simple to manufacture and use. 
 While new players and organizations were able to take a plethora of innovative 
approaches to design, they could not do it alone. Since they were new to the industry, many of 
them partnered with someone that could help with the design. These partnerships ranged from 
doctors and patients to medical device companies. Additionally, some companies utilized 
partnerships for funding, device testing, device manufacturing, and FDA facilitation. Overall, 




Innovation from Old Players 
 Innovative measures taken by old players (pre-existing medical device companies) were 
different than those taken by new players. 33 of the old players created ventilators and 
respiratory-related devices prior to COVID-19, and five did not. Some of the old players 
obtained authorizations for devices that have been approved in other countries and did not 
change the intended use, others may or may not have had 510(k) approval but needed the EUA to 
alter the intended use of the products, and the last set of pre-existing devices were modified for 
the EUA.  
 As seen in the findings, four EUA devices did not exhibit innovation due to the EUA. 
These are the devices that existed before the EUA, were previously used in another country, and 
did not alter the intended use for the EUA. The purpose of the EUA for these four devices was to 
allow them to be used in the U.S. under their correct intended use. 
 The next set of devices showed innovation by changing the intended use. Changing the 
intended use builds on prior knowledge of the device’s technology to repurpose its application, 
which relates to the concept of rapid innovation discussed in the literature review (Von Krogh, 
Kucukkeles, & Ben-Menahem, 2020). There were 12 devices submitted to the EUA that did not 
modify their physical device, but the EUA allowed a temporary change in the intended use. The 
devices under this category exhibit innovation because new knowledge was gained in how the 
device works and how it can contribute to the medical field. The change in intended use occurred 
with devices typically used for people with lung disorders or OSA. Based on the effectiveness of 
these devices treating patients with COVID-19, this innovation may open a new intended use 
post COVID-19; these devices can not only be used for respiratory disorders, but for respiratory 




Eight devices approved through the EUA were existing approved devices with 
modifications. This shows innovation because companies needed to reevaluate and rework their 
devices to fit a different need. They utilized some resources and components they had on hand as 
well as incorporated alternate components due to supply shortages. Product designs were also 
modified to increase safety when treating a person with a viral disease. These types of changes 
may be useful enough to be a permanent modification to the device or provide inspiration for 
new devices.  
Modifications to these pre-existing devices were executed rapidly, which brings an 
interesting point to surface. For modifications such as maximizing performance efficiency, using 
alternate components, and increasing portability, were companies aware of and planning to 
pursue these changes before the EUA? If not, this indicates that the pandemic was the main force 
behind these innovations and the reduced EUA barriers allowed them to be executed quickly. 
There is also a possibility that companies were aware of these changes before the EUA and may 
or may not have intended to pursue them, but the EUA allowed them to get FDA approval, 
although temporary, in a quick manner compared to the traditional FDA process. This could 
indicate that the current regulatory process inhibits innovation as companies are aware of 
changes that would improve their devices but are not implementing them under the typical 
regulatory process. 
Old players did not indicate that they made many changes to their supply chain. Only 
three companies mentioned something in this area, and they all took the same approach - 
utilizing a partner’s supply network to compensate for the shortage of supplies. A similar 
approach was taken for manufacturing. Five companies mentioned utilizing partners to help 




facilitate manufacturing. While the specific actions taken were not stated, if this model is 
executed well, it could have a lasting impact on the company’s manufacturing processes.  
The components and technology utilized by old players were centered around adding 
filters, battery power capabilities, and autoclavable parts into their designs. These additions made 
the devices more suitable for use during COVID-19 but did not fundamentally change the design 
of the ventilators. Two of the old players that did not have ventilator products prior to the EUA 
were able to integrate innovative air processing technologies into their ventilator designs. These 
two devices were solutions to the shortage of compressed medical air, as these new air 
processing technologies can run without compressed air. Advanced air processing technology 
also allowed their devices to be more affordable, one of them being Vayu’s disruptive innovative 
solution to the ventilator industry at $120 (Vayu, 2020). The other innovative approach taken 
was the incorporation of remote access to ventilator devices. This feature allows medical 
personnel to control the ventilators from outside of the room which limits the chance of disease 
transmission and allows medical professionals to monitor multiple patients at a time. Remote 
access is an example of a technology that was capable of being implemented prior to COVID-19, 
but there was no incentive to create devices like this. COVID-19 accelerated the use of this 
technology in the medical field and the EUA allowed it to be implemented quickly. This is a 
technology that would be useful to medical personnel outside of pandemics as well.  
Partnerships were utilized by old players just as much as new players and organizations. 
Most of the old players partnered with a company that could help with manufacturing 
capabilities. This makes sense as medical device companies typically make devices to order, so 
their manufacturing facilities are not built for mass production (Farrugia & Plutowski, 2020). 




to be ramped up for these devices. Less common partnership contributions include funding and 
design. Old players took various approaches to the COVID-19 EUA, but most of them focused 
on small changes to existing devices rather than novel changes. 
Nature of Innovation 
 This section will discuss the nature of innovation from the EUA authorized products. 
Most early-stage innovations, such as innovation from the components used to build the device, 
device design, and technology incorporated, stemmed from new organizations, new players, and 
old players who were not in the ventilator industry. This finding of early-stage innovation 
occurring in new players aligns with what was seen in the literature review. The barriers to small 
firms and new players may significantly impact the amount and type of innovation in the medical 
device industry. The EUA allowed these new players to enter the medical device industry and 
implement their innovative solutions with minimal risk.  
 Old player’s innovation typically stemmed around late-stage product development. Few 
of the devices had fundamental design changes, and the ones that did design came from medical 
device companies from outside the ventilator industry. Most did not have any change or a change 
in intended use and some type of modification. A newer technology that old players from the 
ventilator industry pursued was implementing remote access into ventilator devices. The 
COVID-19 EUA may have helped old players implement an emerging technology that would 
have taken longer to approve otherwise, such as remote access.  
 While there were types of innovation that were unique to new organizations and players 
versus old players, there was some overlap. Both utilized partnerships to help execute 
production. Partnerships can best contribute to innovation when people are working towards a 




future collaborations when the nation is not in a time of crisis, or these partnerships may enable a 
quick reaction time in the event of another pandemic or global crisis.  
 There were many innovative solutions identified throughout this analysis and the 
motivation behind these relates to the concept of frugal innovation. Frugal innovation is “doing 
more, with less, and being creative, innovative, and resourceful in the face of institutional voids 
and resource constraints” (Harris, Bhatti, Buckley, & Sharma, 2020). Frugal innovation is at the 
forefront of solutions utilized during a global pandemic. During COVID-19, there has not only 
been a shortage of medical device supplies and components, but delivery and production 
capabilities were limited due to essential working constraints such as social distancing. 
Additionally, companies needed to figure out how to make things quickly for less money to keep 
up with rising COVID-19 cases and ensure hospitals could afford an adequate supply of 
ventilators.  
Frugal innovations can be seen in the supply chain, manufacturing, and components/ 
technology. Due to the shortage of medical supplies, companies that submitted new solutions to 
the EUA needed to be innovative with their components. Companies took various approaches to 
deal with this issue, such as utilizing their partners’ supply network, using off the shelf or 
commercially available materials, sourcing materials from outside the medical supply chain, 
using DIY components, and using materials already present in hospitals such as manual bag 
masks. These solutions helped relieve the burden on the typical ventilator supply chain, and the 
different approaches minimized the risk of companies running into a shortage again. Additional 
examples of frugal innovation also appeared through components and technology used. Many 




supply chain issue and enhance the product’s manufacturability. Overall, multiple solutions 
stemmed around frugal innovation due to the circumstances of COVID-19. 
In summary, innovation has occurred as a result of the COVID-19 EUA. This innovation 
stemmed in different ways, from the supply chain to manufacturing, to product design. The 























 Innovation in the medical device industry is crucial to meet the constantly changing 
needs of society. As identified in the literature review, innovation in the medical device industry 
has been slow and met with barriers from the regulatory process, but many people said 
innovation was soaring as a response to COVID-19 (Woolliscroft, 2020). COVID-19 opened a 
unique opportunity to explore innovative measures pursued under a process with reduced 
regulatory barriers, the EUA. This thesis looks in detail at the level and types of innovation that 
may have occurred as a result of the EUA.  
 This thesis found that there were three main indicators that the EUA supported 
innovation in the ventilator industry. The first indicator is that there was new entrance to the 
medical device industry. New entrance to the industry was seen not only in companies that 
obtained device authorization, but also in partnerships. New entrance and partnerships 
accelerated innovative measures by applying a diverse and unique set of skills and knowledge to 
the medical device industry. The second indicator is the shift in the types of ventilators seeking 
approval. This shift indicates that innovation was stimulated within certain product codes that 
may not have been explored before. The last indicator is that there were different forms of 
innovation that took place. Innovative approaches were taken regarding the supply chain, 
manufacturing, components, and technology. The drive for innovation in these different areas 
came from constraints created by a global pandemic.  
 Because I could not access the EUA applications, I was not able to determine why EUA 
approval was needed, especially for pre-existing medical devices. If certain supply, 
manufacturing, and design changes are made to a device that would impact its original approved 




collected for this thesis cannot tell us, however, if a firm obtained EUA authorization for changes 
to a device that would typically require a new 510(k) submission. Nor does it indicate if they did 
not pursue the changes prior to the EUA due to the burden of the 510(k) process.  
In conclusion, times of emergency often come with a burst of innovation and an 
opportunity to bypass traditional paths in the FDA regulatory process. This innovation occurred 
when people from all over the world were willing to help fight the COVID-19 battle. There is no 
doubt that COVID-19 impacted the amount of innovation that occurred, but this study shows that 
there is plenty of room for innovation in the medical device industry to grow. The reduction of 
barriers from the EUA resulted in an increase in product improvements and product 
development. While my research saw that innovation did occur, only time will tell if these 
innovations have a lasting impact on the medical device industry. This leaves opportunities for 
future research that will be explained in more detail below.  
Limitations 
 Like any research paper, there were limitations present to this research. The largest 
limitation to this study is the use of publicly available data and analysis of public statements. The 
data available from the FDA for EUA authorizations was minimal and I could not analyze EUA 
submissions or see submissions that were denied or in progress. If this information is available at 
some point in the future, an additional analysis could be completed. Due to the limited FDA 
information, the methods consisted of analyzing public statements and information on 
company’s web pages. When analyzing public statements, there is a risk that the statement may 
be inaccurate or misinterpreted. In addition, public statements are often carefully crafted by the 
firm to highlight specific information, not to reveal all information. As a result, there is likely 




interested in understanding what was novel about a new product, and this is the type of 
information that is often used in marketing or in public statements, it is likely that these 
statements did reflect to some degree the nature of the innovation in each product. In addition, 
the news media was interested in highlighting this innovation and thus solicited information in 
this area. 
The timeline for thesis completion did not allow for product designs to be investigated in 
more detail. Completing further analysis, such as a product decomposition, would provide more 
technical answers and explanations to innovation that occurred due to the EUA. 
Another limitation is only looking at EUA ventilators. The EUA for medical devices was 
also enacted for diagnostic and non-diagnostic devices such as blood purification devices, 
diagnostic tests, personal protective equipment, as well as ventilator tubing and accessories. 
Additionally, there were likely other ventilator responses outside of the EUA which were not 
analyzed. A complete analysis of innovative medical device responses for COVID-19 would 
increase this research paper’s external validity. 
Implications for Research 
While completing this thesis, multiple questions arose that would be interesting to look 
into for further research. First, as just discussed, additional details and information could be 
researched to validate this thesis’s findings. This includes requesting additional information on 
EUA submissions from the FDA and conducting an in-depth analysis of the product design and 
components of each EUA device. 
Next, there are multiple avenues for future work that can build on the information from 
this thesis while investigating different research questions. One of these would-be conducting 




This would provide an insider’s perspective on the innovation during this time and would 
validate some questions such as COVID-19 and the EUA being the source of this innovation.  
Another study that can be done is to do a detailed analysis on if any devices got full FDA 
approval, which ones, and if they play a prevalent role in the ventilator market. This study would 
not be able to be done until some time after the EUA is revoked and COVID-19 is under control 
to ensure the results do not just represent lingering effects from COVID-19. 
Building off the literature review, some papers mentioned a negative perception of 
working with the FDA. It would be interesting to investigate interactions between companies and 
the FDA before and during the EUA process and conduct a sentiment analysis on communication 
before, during, and after the EUA. This may provide valuable information regarding how firms’ 
perceptions of their interactions with the FDA impacts innovations as well. 
Implications for Policy and Policy Recommendations 
 This section will discuss policy implications and provide policy recommendations to 
attempt to increase innovation in the medical device industry outside of times of emergency. 
EUA 
The goal of the EUA is to “promote the development and availability of specific medical 
devices and products during national emergencies” (FDA EUA, 2017). The EUA is not a process 
that was created specifically for COVID-19. It has been used to manage other viral diseases, 
including but not limited to H7N9 in 2013, 2014 Ebola, and the Zika virus. The EUA during 
COVID-19 was enacted in response to the need for various medical solutions from diagnostic to 
nondiagnostic devices, including ventilators.  
The EUA appears to have been successful in its goal of promoting the development and 




production of thousands of devices, including those by Ventec and GM (VenTec Life Systems, 
2020). The EUA supported creative measures and innovative thinking that sometimes went 
beyond what was needed to meet immediate market demand. We also saw that partnerships and 
collaborations established in response to the EUA catalyzed the development of innovative 
solutions. Based on the performance of the EUA, I would recommend that FDA continue 
utilizing the EUA in times of emergency.  
Promote Collaboration 
In addition to the EUA, the FDA should promote partnerships for small firms and non-
traditional medical device companies. In the analysis, we saw that partnerships enabled the 
creation and production of authorized devices. If the FDA can foster partnerships, that could 
create a more consistent flow of innovation in the medical device industry. This could be done 
by establishing a program that facilitates partnerships between companies working towards a 
shared goal. Partnerships between universities, small firms, and established medical device 
companies as well as medical device companies with other industries will likely stimulate 
innovation. 
Proactively Responding to Pandemic Plans 
 Prior to the pandemic, the White House Homeland Security Council outlined the National 
Strategy for Pandemic Influenza, Implementation Plan in 2006. This document is meant to be a 
live document to be refined as future pandemics occur (Homeland Security Council, 2006). 
There have been a few public health crises since 2006, but the document has not been updated. 
This document identifies some medical resources that are scarce during a pandemic such as, 
hospital and ICU beds, ventilators, and other medical services. Medical staff experience high 




functions such as working in a different unit than their specialized training. This requires 
ventilators and medical equipment created in a pandemic to use intuitive, innovative solutions so 
the device can be used by someone not specially trained to use it.  
Additionally, the Department of Health and Human Services (HHS) identified a 
ventilator shortage in 2006 and determined that an additional 70,000 would be needed in the case 
of a moderate pandemic. The limited national stockpile of ventilators consisted of large, 
expensive, difficult to use machines. A partnership was established to develop optimized devices 
that cost less than $3,000, ready for mass production by 2010 (Kulish, Kliff, & Silver-Greenberg, 
2020). By 2014, the company asked to get out of the government deal, and in the end, no 
ventilators were produced for the national stockpile. The fact that 77 devices could be modified 
or created by companies in various industries over five months, compared to a four turned 8-year 
project that did not result in anything, shows there is a lack of incentives to develop new and 
innovative products needed for emergency situations in the medical device industry under 
normal conditions. 
 It is apparent that the government is aware of the impracticality of current full-service 
ventilators for both function and quantity during a pandemic. There are multiple regulatory plans 
in place to try to manage this issue, but all these strategies call to fix the problem after it occurs. 
As soon as a gap in the medical device industry is recognized, such as the need for affordable, 
user-friendly ventilators that can be easily mass-produced, this knowledge should be 
incorporated into the industry as soon as possible. Suppose the government can foster and help 
develop these ideas earlier to avoid stagnancy in innovation in the medical device industry? In 
that case, companies have the incentive to implement these innovative solutions at any point 





One way the government could encourage medical device companies to fill known gaps 
in the industry is to establish a government-run database of open-source designs. When a gap is 
realized in the medical device industry, action can be taken to incentivize companies to produce 
an open-source design. This approach would be less time-intensive for companies compared to 
designing and fulfilling an order for thousands of devices. The FDA would best manage the 
database as they can work with a company to develop a suitable device that meets all the 
requirements. This recommendation could be incentivized by implementing a tax relief or other 
type of financial incentive. Companies may be hesitant to create open-source designs as 
profitability generally revolves around intellectual property rights. A financial incentive would 
provide some sort of return on investments to the company. Additionally, if the open-source 
designs are kept private until an emergency like COVID-19 occurs, companies may be more 
willing to contribute to this database. 
Incentivize Frugal and Accessible Innovation 
 The last recommendation I have is to incentivize the creation of accessible medical 
devices. This can be approached from multiple angles. The first one is incorporating increased 
usability into medical device designs and the second is designing for increased accessibility. 
Ventilators are only one example of devices that are very expensive and require highly trained 
professionals to use them. Underdeveloped communities and countries have minimal access to 
many medical devices and companies have little incentive to fill this need. From the COVID-19 
EUA, we saw innovative frugal solutions that were easier to use, cost less, and could be used 
various locations making them a good option for underdeveloped communities. Incentivizing 




device categories. This could be done by expanding commercialization assistance programs 
(CAP). The National Institute of Health (NIH) implemented a CAP program in 2014 to help 
small businesses develop and commercialize their devices. They have been able to help over 
1,000 companies since then (NIH CAP, 2020). The NIH could create another CAP program or 
build on the current one to involve specialized goals, such as creating accessible devices. Their 
experience with this program and recognition of innovative solutions created by small businesses 
would provide companies with an excellent opportunity to focus on the need for accessible and 
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Beijing Aeonmed Co., Ltd 3/25/2020 VG70 ventilator 
Shenzhen Mindray Biomedical 
Electronics 
3/28/2020 Mindray SV300/SV600/SV800 ventilators 
Vyaire Medical, Inc. 3/28/2020 LTV2 model 2200 and LTV model 2150 
RESMED 3/30/2020 
Lumis 150 VPAP ST (Amended 
April 17, 2020) 
RESMED 3/30/2020 Stellar 150 
Amsino 3/31/2020 
YUWELLÂ® YH-730 Bi-level PAP and YH-
830 Bi-level PAP 
Inovytec 3/31/2020 Ventway Sparrow 
RESMED 3/31/2020 
AirCurve 
S T (Amended 
April 17, 2020) 
RESMED 3/31/2020 Flexo Bi-Level ST 
RESMED 3/31/2020 GA ST 
Philips Respironics 04/01/2020 VX850 Ventilator 
BMC Medical Co., LTD 04/02/2020 Y-30T 
BMC Medical Co., LTD 04/02/2020 Luna GPAP 25A- LG3700 
Dragerwerk AG & CO. KGaA 04/02/2020 Evita V800 and Evita V600 
Dragerwerk AG & CO. KGaA 04/03/2020 Babylog VN800 and VN600 
GE Healthcare 04/03/2020 pNeuton Model A-E Ventilator 
Covidien LLC 04/05/2020 Puritan Bennett 560 Ventilator System 
CoLabs 04/06/2020 COVID Ventor 
MEKICS Co,. Ltd 04/06/2020 MTV1000 ventilator 
VenTec Life Systems 04/07/2020 V+Pro Emergency Ventilator 
Dragerwerk AG & CO. KGaA 04/07/2020 Atlan A350 and Atlan A350 XL 
Philips Respironics 04/08/2020 E30 ventilator 
AMBULANC TECH. CO.,LTD 04/08/2020 Models 6000S, T5, T7 
Incoba LLC 04/08/2020 Apogee 
SecondBreath LLC 4/13/2020 Pneumatic Resuscitator device 
University of Minnesota Medical 
School and Boston Scientific 
Corporation 
4/14/2020 Coventor Adult Manual Resuscitator Compressor 
Umbulizer 4/14/2020 UMV-001 EUA 
Hillrom 4/16/2020 MetaNeb 4 
Spiro Devices LLC 4/17/2020 Spiro Wave (Amended June 8, 2020) 
PVA 4/17/2020 PREVENT 
RESMED 4/17/2020 AirCurve 10 ST-A 
3B Medical Inc 4/20/2020 Luna G3 B30VT 
Resvent 4/20/2020 iBreeze PAP 
Virgin Orbit 4/22/2020 
Virgin Orbit Resuscitator (Amended April 23, 
2020) 
Amsino 4/23/2020 YUWELL YH-725 BiPAP 








SLS Medical Technology Corp. 
Ltd. 
4/24/2020 CP101/CP101S Series 
Zhejiang LifeMed Technology 
Co., Ltd. 
4/24/2020 
LA Series Ventilators LA20C, LA20A, LA20B, 
LA20B, LA25B, LA25B 
Resvent Medical Technology 
CO., Ltd's 
4/27/2020 iBreeze 30STA device 
Shenzhen Yamind Medical Tech 4/28/2020 
CPAP Devices: DM28-20C-G; Auto CPAP 
Devices: DM28-20A-W, DM28-20A-WP; 
BiPAP Devices: DM28-20S-G, DM28-20SA-G, 
DM28-20ST-G, DM28-25S-B, DM28- 25SA-
BP, DM28-25ST-BP, DM28-30ST-B, DM28-
30ST-BP, DM28-30STA-BP 
NASA Jet Propulsion 
Laboratory 
4/30/2020 VITAL ventilator 
Venti-Now 4/30/2020 Venti-Now Resuscitator Model JM-P2020A 
Wilcox Industries Corp 05/01/2020 
Wilcox PATRIOT SAVR (Amended July 21, 
2020) 
Wilcox Industries Corp 05/01/2020 Wilcox PATRIOT SAVR 
Elemaster S.p.S. Technologie 
Elettroniche 
05/01/2020 Mechanical Ventilator Milano (MVM) 
ZIBO ZHONGXUN MEDICAL 
EQUIPMENT CO. LTD 
05/02/2020 ZXH-550 
JIUXIN MEDICAL 05/02/2020 JIXI H-100 
BMC Medical Co., LTD 05/02/2020 Luna G3 BPAP S/T- LG3800-G3 B30VT 
Vayu Global Health Innovations 05/05/2020 
Vayu bubble Continuous Positive Airway 
Pressure Circuit ("Vayu bCPAP') 
Hunan Beyond Medical 
Technology Co., Ltd 
05/06/2020 BEYOND B30P BiPAP 
Hunan Beyond Medical 
Technology Co., Ltd 
05/06/2020 BEYOND C20A CPAP 
Guangzhou Hypnus Healthcare 
Co., Ltd. 
05/06/2020 Hypnus ST730 
AutoMedX Inc. 5/7/2020 SAVe II+ (M50016, M50017) 
Taiyuan Shanghai Medical 05/08/2020 Fabius Plus / Fabius Plus XL 
Somnetics International, Inc. 05/08/2020 Transcend 3 BiPAP 
Lanick Med Systems LLC 05/07/2020 Lyra x1 and Lyra x2 Ventilators 
CMI Health 5/15/2020 Beijing Aeonmed Shangrila510S 
SysMed (China) Co., Ltd 5/18/2020 
VM series- DPAP20 Plus, DPAP25 Plus, 
DPAP25 Pro, DPAP30 Pro 
SysMed (China) Co., Ltd 5/20/2020 
Resware BI 20 S, Resware BI Auto S, Resware 
BI 25 S/T, Resware BI 30 S/T, ZiZ Auto, Aurora 
Bi-Level S, Aurora Bi-Level S/T, Aurora Bi-
Level Auto S 
Origin Medical Devices Inc. 5/22/2020 Panther 5 Model P5DLVENT 
Guangzhou Hypnus Healthcare 
Co., Ltd. 
5/22/2020 BA825W, BA825, ST830W and ST830 








NASA Jet Propulsion 
Laboratory 
4/30/2020 VITAL Compressor 
BioMedInnovations, LLC 06/08/2020 SuppleVent 
Nanotronics Imaging, Inc 06/09/2020 nHale BiPAP device 
Enexor BioEnergy, LLC 6/10/2020 X-VENT Emergency Ventilator 
NeoNatal Rescue, LLC 6/17/2020 AdultLife Pro Ventilator 
World Ventilator Foundation 
(WVF) 
6/19/2020 WorldVent Ventilator 
Air Boost 6/24/2020 AustinP51 
Sagico USA, LLC 6/26/2020 V2O SAGICO SYSTEM 
Stewart & Stevenson Healthcare 
Technologies, LLC 
6/26/2020 Apollo ABVM 
LifeMech, Inc. 7/31/2020 LifeMech A-VS 
Nanotronics Imaging, Inc 8/4/2020 nHale BiPAP device 
VORTRAN Medical Technology 
1, INC 
8/4/2020 VORTRAN GO2VENT with PEEP Valve 
Hillrom 8/7/2020 
Life 2000 Ventilation System Product No. BT-
V5 
Breas Medical Inc 8/18/2020 Z2 Bilevel 
MICo Medical s.r.o. 8/21/2020 MICo Medical CoroVent 
 
Appendix 2: Products with No Data Found 
Company Product 
RESMED GA ST 
Zhejiang LifeMed Technology Co., Ltd. LA Series Ventilators LA20C, LA20A, LA20B, 
LA20B, LA25B, LA25B 
ZIBO ZHONGXUN MEDICAL EQUIPMENT 
CO. LTD 
ZXH-550 
Hunan Beyond Medical Technology Co., Ltd BEYOND B30P BiPAP 
Hunan Beyond Medical Technology Co., Ltd BEYOND C20A CPAP 
Taiyuan Shanghai Medical Fabius Plus / Fabius Plus XL 
BMC Medical Luna G3 BPAP S/T- LG3800-G3 B30VT 
Resmed Flexo Bi-level ST 
Incoba Apogee 
SysMed (China) Resware and Aurora Series 
 
Appendix 3: Repeat Devices 
Company Product 
Wilcox Industries Patriot SAVr 
AutoMedX Inc. SAVe II Series Ventilator 
Nanotronics Imaging nHale BiPAP 
NASA Vital 
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• James Pasley. (April 24, 2020 Friday). Singapore's richest man is getting $1 billion richer each month 
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• (April 16, 2020 Thursday). Vyaire Announces HHS Contract to Produce 22,000 Ventilators. Contify Life 
Science News. 
• Vyaire CEO Speaks with McKinsey about Company's COVID-19 Response. (n.d.). Retrieved December 
20, 2020, from https://www.vyaire.com/covid-19-news/vyaire-ceo-speaks-mckinsey-about-companys-
covid-19-response 
RESMED • (April 30, 2020 Thursday). Q3 2020 Resmed Inc Earnings Call - Final. FD (Fair Disclosure) Wire. 
• Coronavirus Response. (2020, June 16). Retrieved December 20, 2020, from https://www.resmed.com/en-
us/covid-19/  
Inovytec • (April 21, 2020 Tuesday). Israel fast-tracks ventilator innovations for Covid-19 care. Pharma & 
Healthcare Monitor Worldwide. 
• Rubinstein, C. (2020, May 20). From Missiles To Deadly Viruses: Iron Dome Architects Develop 
Innovative Defenses Against COVID-19. Retrieved December 20, 2020, from 
https://www.forbes.com/sites/carrierubinstein/2020/05/20/from-missiles-to-deadly-viruses-iron-dome-
architects-develop-innovative-defenses-against-covid-19/?sh=522c38455542  
• Etsion, U. (2020, March 22). Portable Medical Device Developer Inovytec to Provide Israeli Defense 
Ministry with 1,000 Respiratory Machines. Retrieved December 20, 2020, from 
https://www.calcalistech.com/ctech/articles/0,7340,L-3802855,00.html  
• VENTWAY SPARROW. (n.d.). Retrieved December 20, 2020, from https://www.inovytec.com/ventway/  
• First in Critical Care Response. (n.d.). Retrieved December 20, 2020, from https://www.inovytec.com/  
Philips Respironics • VX850 Critical care ventilator. (n.d.). Retrieved December 20, 2020, from 
https://www.usa.philips.com/healthcare/product/HC850013/vx850-critical-care-ventilator/overview  
• COVID-19 response & healthcare solutions: Philips Healthcare. (n.d.). Retrieved December 20, 2020, 





BMC Medical Co., 
LTD 
• (April 13, 2020 Monday). Chinese companies race to supply ventilators as global demand surges. People's 
Daily Online - English. 
• BMC Medical. (n.d.). Retrieved December 20, 2020, from http://en.bmc-medical.com/covid-19  
Dragerwerk AG & 
CO. KGaA 
• Coronavirus – Drager’s Important Information during the Novel Coronavirus Outbreak. (n.d.) retrieved 
December 20, 2020, from https://www.draeger.com/en-us_us/Novel-Coronavirus-Outbreak  
• Kamann, M. (March 19, 2020). We do our best to fulfill our social supply obligation. (n.d.) retrieved 
December 20, 2020, from https://www.draeger.com/Library/Content/23e_corona_effects.pdf  
• GlobeNewswire. (2020, October 21). Dräger Wins 2020 Frost & Sullivan Global Technology Innovation 
Leadership Award. Retrieved December 20, 2020, from 
https://www.newsr.in/n/Press%20Releases/1zlu618lfd/Dr%C3%A4ger-Wins-2020-Frost-Sullivan-Global-
Technology.htm  
• (n.d.) Retrieved December 20, 2020, from  
https://www.draeger.com/en_aunz/Hospital/Products/Anaesthesia-Workstations/Anaesthesia-
Machines/Atlan-A350-A350-XL#benefits  
GE Healthcare • (March 24, 2020 Tuesday). Briefing.com: Hourly In Play (R) - 18:00 ET. Briefing.com. 
• (April 2, 2020 Thursday). -Ford to Produce 50,000 Ventilators in Michigan in Next 100 Days; Partnering 
with GE Healthcare Will Help Coronavirus Patients; Ford, in collaboration with GE Healthcare, will 
leverage the design of Airon Corp.'s FDA-cleared ventilator to produce in Michigan; With the full weight 
of the UAW behind the venture and the full power of Ford and GE Healthcare, production of the 
GE/Airon Model A-E ventilator is targeted to start the week of April 20 at Ford's Rawsonville (Mich.) 
Components Plant; Ford expects to produce 50,000 of the ventilators within the next 100 days, with the 
ability to produce 30,000 a month thereafter as needed. ENP Newswire. 
• ICU Ventilation User Resources. (n.d.). Retrieved December 20, 2020, from 
https://www.gehealthcare.com/products/ICU-Ventilation-User-Resources  
Covidien LLC • (April 10, 2020 Friday). FDA grants emergency nod to ventilators from Medtronic, other 
companies. Pharma & Healthcare Monitor Worldwide. 
• Innovators Unite: Unexpected Partners Join Forces In Fight Against Covid-19. (n.d.). Retrieved December 
20, 2020, from https://news.medtronic.com/innovators-unite-for-covid19  
CoLabs • (April 10, 2020 Friday). FDA grants emergency nod to ventilators from Medtronic, other 
companies. Pharma & Healthcare Monitor Worldwide. 
• About Us. (n.d.). Retrieved December 20, 2020, from https://www.covidventor.com/about-us  
MEKICS Co,. Ltd • (April 8, 2020 Wednesday). 11:25 EDT Biolase partners with MEKICS to make, supply ventilators amid 
COVID-19 spread. Theflyonthewall.com. 





• (September 1, 2020 Tuesday). General Motors and Ventec Life Systems Complete Delivery of 30,000 
V+Pro Critical Care Ventilators. PR Newswire. 
• (April 17, 2020 Friday). GM-Ventec critical care V+Pro ventilators ready for delivery. The Saudi Gazette. 
Philips Respironics • RT Staff. (April 15, 2020 Wednesday). Philips E30 Ventilator Launches with FDA 
Authorization. Newstex Blogs RT: For Decision Makers in Respiratory Care. 
• (May 9, 2020 Saturday). Philips Ventilator Respironics E30 for ICU COVID-19 Patients. Pharma & 
Healthcare Monitor Worldwide. 





• (September 28, 2020 Monday). Ambulanc (Shenzhen) Tech Ltd Co secures contract for 
Ventilators. Pivotal Sources. 
• T7 Ventilator. (n.d.). Retrieved December 20, 2020, from 
http://www.ambulgroup.com/en/proview.php?SortID=59  
SecondBreath LLC • (April 14, 2020). Portman Helps Facilitate FDA Approval for Production of Ventilators at Cleveland-
Based SecondBreath; Sen. Rob Portman (R-OH) News Release. Congressional Documents and 
Publications. 
• States News Service. (May 7, 2020 Thursday). ON SENATE FLOOR, PORTMAN DISCUSSES HIS 
EFFORTS TO HELP OHIO AND THE WAY FORWARD IN THIS CORONAVIRUS 
PANDEMIC. States News Service. 
• RACHEL ABBEY McCAFFERTY. (April 27, 2020). EIGHT OVER 80; Dan T. Moore III, 80. Crain's 
Cleveland Business. 




School and Boston 
Scientific Corporation 
• (June 3, 2020 Wednesday). U of M releases Coventor ventilator design as open-source. Pharma & 
Healthcare Monitor Worldwide. 
• (April 16, 2020 Thursday). FDA authorizes production of a new ventilator that costs up to 25x less than 
existing devices. iCrowdNewswire (English). 
• Adangol. (2020, March 24). COVID-19 Ventilator. Retrieved December 20, 2020, from 
https://med.umn.edu/covid19Ventilator  
Umbulizer • States News Service. (April 24, 2020 Friday). PRESIDENT'S INNOVATION CHALLENGE TAPS 
STUDENTS' INGENUITY. States News Service.  






Hillrom • (May 1, 2020 Friday). Hillrom's Fiscal Second Quarter Financial Results Exceed Guidance; Hillrom 
Supports Global COVID-19 Response With New Critical Care Products and Expanded Production. PR 
Newswire. 
• (April 22, 2020 Wednesday). Hillrom Introduces Five New Innovations To Help Caregivers Fight 
COVID-19. Pharma & Healthcare Monitor Worldwide. 
• MetaNeb System. (n.d.). Retrieved December 20, 2020, from https://www.hillrom.com/en/products/the-
metaneb-system/  
• Life2000 Ventilator. (n.d.). Retrieved December 20, 2020, from 
https://www.hillrom.com/en/products/life-2000-acute-care/  
• Hillrom More Than Doubles Production Of Critical Care Products, Including Ventilators, Hospital Beds 




Spiro Devices LLC • (April 27, 2020 Monday). Spiro Wave emergency ventilator gains FDA authorization to address COVID-
19 demand. Greentechlead.com. 
• Spiro Wave. (n.d.). Retrieved December 20, 2020, from https://www.10xbeta.com/spiro-wave  
PVA • Medgadget Editors. (April 20, 2020 Monday). PVA Emergency Ventilator Ready for Production. Newstex 
Blogs Medgadget. 
• (April 22, 2020 Wednesday). Colonie company gets FDA approval to make emergency 
ventilators. Pharma & Healthcare Monitor Worldwide. 
• (August 26, 2020 Wednesday). FDA Enforcement Report: PVA, PREVENT is an FDA-authorized 
emergency ventilator designed to treat patients suffering from COVID-19 respiratory failure. This 
motorized device automatically compresses a resuscitator bag to provide air to the lungs of a COVID-19 
patient, eliminating the human error and fatigue that results from manual actuation. PREVENT is 
indicated for emergency more.... Impact News Service. 
• PREVENT. (n.d.). Retrieved December 20, 2020, from https://pva.net/products/custom-
automation/prevent  
3B Medical Inc • (April 9, 2020 Thursday). Shook Attorney Helps Manufacturer Gain Approval For Medical Device 
Product to Help COVID-19 Patients. Impact Financial News. 
Virgin Orbit • (April 24, 2020 Friday). Virgin Orbit s ventilators gain FDA authorization, deliveries to hospitals will start 
within days. iCrowdNewswire (English). 
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• (May 1, 2020 Friday). NASA Gets EUA Thumbs-Up: FDA Allows Emergency Use Of Space Agency's 
VITAL Ventilator. Medtech Insight. 
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